Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

37.41 +0.74 (+2.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceu

< Previous 1 2 3 4 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades 
Via Benzinga
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: 
Via Benzinga
Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance
Via Benzinga
Ultragenyx's Neurogenetic Disorder Candidate Shows Favorable Tolerability, Clinical Activity
Via Benzinga
Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M
Via Benzinga
Expert Ratings for Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: Ultragenyx Pharmaceutical Q2 Earnings
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward"
Via Benzinga
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
Via Benzinga
Earnings Scheduled For July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday. 
Via Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue... 
Via Benzinga
Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday. 
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
Netflix To $210? Here's The Biggest Price Target Changes For Friday
Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ultragenyx Pharmaceutical's Earnings Outlook
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.